In this blog for people with Raynaud’s phenomenon, Dr Kevin Su, a Rheumatologist from Australia, looks at the latest Cochrane evidence on vasodilator drugs. Katie LeBlanc, a patient advocate, reflects on her experiences.
Take home points
Raynaud’s phenomenon can be painful and at times cause issues with function in the hands. For those who suffer with this condition, at times, there seems to be no relief despite best efforts to avoid triggers and keeping your body and limbs warm. As a Rheumatologist, I see this a lot. My patients, many of whom do not have a rheumatic illness, but are referred by their family doctors because they’re not sure what do, look to me for support.
Patients who persist to have symptoms despite lifestyle strategies are commonly prescribed a family of medications typically used in hypertension (or high blood pressure) called calcium channel blockers. Although this is frequently a first line treatment, the evidence for their use is mixed (1, 2).
This is the reason that my group and I reviewed and summarised the latest evidence on another treatment in our latest Cochrane systemic review ‘Vasodilators in Raynaud’s Phenomenon’ (3).
Raynaud’s phenomenon is a condition where the blood vessels in the hands and feet narrow and widen in response to triggers like cold and stress. As the vessels narrow then widen over seconds to minutes, the ‘classic’ colour changes of white, red then purple occur.
This phenomenon can occur with rheumatic illnesses like Lupus or Rheumatoid arthritis, but is also very common in patients without any illness at all. We call this Primary Raynaud’s Phenomenon and this was the focus of the review.
Cochrane evidence on vasodilators
The latest Cochrane Review: ‘Vasodilators for primary Raynaud’s phenomenon’ included people over the age of 18, who did not have a history of rheumatic illnesses and were not taking any medications that caused blood vessels to narrow. We also did not include patients who had narrowing of their blood vessels from other medical conditions.
The review (published in May 2021) included 15 studies. We wanted to make sure every type of vasodilator was explored for people with this condition, so we included treatments taken by mouth, as well as those that are applied to the skin, and those that are injected into the veins or arteries.
We wanted to look at features that would be helpful for both patients and doctors treating the condition. So we wanted to see whether the frequency, severity, and length of attacks would be improved and, for the doctors, whether there would be any changes to blood vessel scans and disease scores (which are really only used in research studies). We obviously also wanted to look out for any potential harms of the medications.
Collectively, the studies looked at several medications.
Of note, some vasodilators may be of benefit:
- One particular medication, moxisylyte, may have reduced the number of episodes, their severity and how long they lasted, but this was in one very small study. However, patients were also more likely to experience side effects taking moxisylyte, which can include heartburn, flushing and taste alterations.
- Another medication, ketanserin, may have slightly reduced the number of attacks per week but the evidence is very uncertain.
- In one study, gylceryl trinitrate (a medication usually for patients who experience angina) may have slightly reduced the severity of attacks, but the clinical importance of this is unclear and the evidence is very uncertain.
However, of note, some vasodilators may do more harm than good:
- There is the suggestion that other agents such beraprost (prostaglandin inhibitor) and dazoxiben (thromboxane synthease inhibitor) may cause a mild increase in frequency of attacks, although the extent of the effect is unclear.
- ACE inhibitors, as a class of medications may also cause mild increases in frequency and duration of attacks, but again, the extent is unclear.
Uncertain evidence about the potential benefits and harms of vasodilators
Unfortunately, we found that the majority of the studies were not clear about how the study was performed. In particular, how they selected the people in the study. Or, the studies had some design flaws that made it hard to know if it was really a medication effect that was seen. It’s hard to tell how important these results are for patients and doctors.
Ongoing research into treatments for Raynaud’s phenomenon
Despite the problems with the current evidence, all hope is not lost. There are currently two well designed studies, that are ongoing, looking at two commonly used oral medications for the treatment of Raynaud’s phenomenon, so watch this space.
Further support and resources for people with Raynaud’s phenomenon
There is also lots of information out there for people who have Raynaud’s phenomenon. Here are some websites that you might find useful from some major organisations around the world and the UK:
- American College of Rheumatology
- Versus Arthritis (a UK based not-for-profit organisation)
- Musculoskeletal Australia
- NHS Choices
Additional ways to manage Raynaud’s symptoms
Finally, despite the limited evidence that is available, the advice that I typically offer to patients who suffer from Raynaud’s phenomenon is this:
- keep warm, go buy that set of nice winter gloves that you have been eyeing up; as we know that keeping your limbs AND body warm is very effective.
- avoid triggers that may cause Raynaud’s to occur. Sometimes, it may not be something that you’ve thought of. For example, handheld power tools can be a trigger!
- if you smoke, stopping can be really helpful. Aside from the heart and cancer risks that come with it, smoking can also make Raynaud’s phenomenon worse.
For anyone who thinks they might have Raynaud’s, I’d say:
- Please see your doctor if you get colour changes and discomfort in your fingers and toes, we want to make sure you get assessed for underlying issues and get appropriate treatment.
Reflections from Katie, a patient advocate:
“As a Cochrane author and patient advocate, I recently completed the peer review for “Vasodilators for primary Raynaud’s phenomenon”. I have been reviewing and summarizing systematic reviews of clinical trials for Cochrane since 2001. During that time, I was diagnosed with Raynaud’s phenomenon and I have dealt with the pain and complications of the disease over the years. I have also provided supportive care for Raynaud’s patients. The following summary is a “bird’s eye view” of my experiences with Raynaud’s phenomenon:
Initially I was shocked to see my fingers change colour, from white to bluish-grey and finally red when warmed up. The pain when warming up was overwhelming and often brought tears to my eyes.
Although I have not used calcium channel blockers, my experience with vasodilators has been positive. My current treatment consists of the application of nitroglycerin to the affected fingers and toes. Scientific evidence regarding this particular treatment is uncertain. However my physician is pleased that the treatment has increased my circulation and ultimately decreased the severity of pain associated with the narrowing of my blood vessels in the affected extremities.
To alleviate the symptoms, I have found it necessary to avoid cold weather and particularly rapidly changing temperatures if possible. During the Canadian winter, I wear lined mittens inside thermal gloves and fleece lined thermal boots with the added protection of alpaca or thermal socks. The mittens increase finger movement and warmth and the fleece prevents friction inside the thermal boots.”
Please note, we cannot give specific medical advice and do not publish comments that link to individual pages requesting donations or to commercial sites, or appear to endorse commercial products. We welcome diverse views and encourage discussion but we ask that comments are respectful and reserve the right to not publish any we consider offensive. Cochrane UK does not fact check – or endorse – readers’ comments, including any treatments mentioned.
Kevin and Katie have nothing to declare.
Kevin’s biography appears below. Read Katie’s biography.